Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Working Capital Changes (2016 - 2025)

Corcept Therapeutics' Other Working Capital Changes history spans 10 years, with the latest figure at $17.5 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 104.88% year-over-year to $17.5 million; the TTM value through Dec 2025 reached $18.9 million, up 27315.94%, while the annual FY2025 figure was $18.9 million, 27315.94% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $17.5 million at Corcept Therapeutics, up from $1.8 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $17.5 million in Q4 2025 and bottomed at -$6.6 million in Q3 2024.
  • The 5-year median for Other Working Capital Changes is -$331000.0 (2025), against an average of $1.3 million.
  • The largest annual shift saw Other Working Capital Changes surged 950.39% in 2022 before it plummeted 9058.33% in 2024.
  • A 5-year view of Other Working Capital Changes shows it stood at -$1.1 million in 2021, then surged by 824.31% to $8.2 million in 2022, then crashed by 67.07% to $2.7 million in 2023, then skyrocketed by 216.2% to $8.5 million in 2024, then soared by 104.88% to $17.5 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Other Working Capital Changes are $17.5 million (Q4 2025), $1.8 million (Q3 2025), and -$331000.0 (Q2 2025).